Spear Holdings RSC Ltd Reduces Stock Holdings in Eli Lilly and Company $LLY

Spear Holdings RSC Ltd lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,390 shares of the company’s stock after selling 7,810 shares during the quarter. Eli Lilly and Company accounts for about 1.9% of Spear Holdings RSC Ltd’s holdings, making the stock its 17th biggest holding. Spear Holdings RSC Ltd’s holdings in Eli Lilly and Company were worth $34,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $29,000. Steph & Co. boosted its position in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $31,000. Finally, Bare Financial Services Inc increased its stake in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a report on Wednesday, January 14th. Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. Bank of America cut their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research note on Monday, December 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $1,174.61.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Launched a Phase 3b dosing study for retatrutide in obesity, advancing a leading obesity candidate toward optimized dosing and broader label/market potential. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Retatrutide trial data suggest potential knee osteoarthritis symptom benefit tied to weight loss — could expand clinical and commercial appeal beyond pure weight metrics. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: SURMOUNT‑REAL UK (phase 4) will provide real‑world tirzepatide data in obesity — useful for uptake, payer conversations and long‑term market sizing. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: FDA granted Breakthrough Therapy designation to sofetabart (mipitecan) for certain platinum‑resistant ovarian cancer patients — accelerates development path and raises long-term oncology upside. FDA Grants Breakthrough Therapy Tag to LLY’s Ovarian Cancer Candidate
• Positive Sentiment: Initiated a Phase 2 oral pain program for diabetic nerve pain — diversification of pipeline into high‑unmet‑need pain indications could add medium‑term value. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Announced a Phase 1 PET tracer imaging study to broaden oncology imaging capabilities — early stage, strategic but long‑timeline impact. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Neutral Sentiment: Confirmed Q4 2025 earnings date (Feb 4) — sets the calendar for next major catalyst and likely some pre‑earnings positioning. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Market commentary pieces (buy/preview, breakout) and an explainer on why LLY is up today summarize investor enthusiasm and momentum ahead of results; useful but opinion‑driven. Why Eli Lilly (LLY) stock is up today
• Negative Sentiment: Coverage notes Novo Nordisk’s new CEO is expected to intensify competition in obesity treatments — a reminder of pricing, market‑share and reimbursement risks. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Eli Lilly and Company Trading Up 0.8%

Shares of NYSE:LLY opened at $1,087.63 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company’s 50-day moving average price is $1,056.39 and its 200 day moving average price is $878.04. The company has a market cap of $1.03 trillion, a PE ratio of 53.21, a P/E/G ratio of 0.81 and a beta of 0.35. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.